Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab. [PDF]
HeadacheNikitina V +3 more
europepmc +1 more source
A National Cross-Sectional Survey on Real-World Experiences of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody Use in Adults with Migraine in Finland. [PDF]
Pain TherCasey CS +8 more
europepmc +1 more source
Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription. [PDF]
Ther Adv Neurol DisordKatsuki M +3 more
europepmc +1 more source
Prophylactic Management of Vestibular Migraine: A Systematic Review. [PDF]
Ann Clin Transl NeurolAlmohammed HA +11 more
europepmc +1 more source
Increased infection risk in patients on preventive CGRP-targeting therapies- a meta-analysis and clinical effect assessment. [PDF]
J Headache PainStraburzyński M +9 more
europepmc +1 more source
Genetic migraine disorders and the response to calcitonin gene-related peptide antagonist treatment. [PDF]
HeadacheKuczynski AM, Kingston WS.
europepmc +1 more source
Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine. [PDF]
Curr Pain Headache RepNicol KS, Burkett JG.
europepmc +1 more source
Impact of anti-CGRP monoclonal antibodies on treatment satisfaction and quality of life in patients with resistant migraine: a retrospective real-world study. [PDF]
BMC NeurolCardona-Roca L +5 more
europepmc +1 more source
Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies. [PDF]
Neurol TherBuse DC, Versijpt J, Diener HC.
europepmc +1 more source